Eric Rhodes, CEO at ERS Genomics, believes the field will keep growing in 2024: “ The CRISPR/Cas9 sector is poised to continue its remarkable growth trajectory through 2024, driven by the first approved clinical application in the U.K. for treating sickle-cell disease and transfusion-dependent beta-thalassemia (TDT).
Eric Rhodes, CEO at ERS Genomics, believes the field will keep growing in 2024: “ The CRISPR/Cas9 sector is poised to continue its remarkable growth trajectory through 2024, driven by the first approved clinical application in the U.K. for treating sickle-cell disease and transfusion-dependent beta-thalassemia (TDT). Strengthening this prediction is the recent U.S. Food and Drug Administration (FDA) approval of Casgevy for TDT, which further underscores the technology’s potential to cure previously untreatable diseases.”